ArticleExperimental & molecular medicine2026
S100A8/S100A9 released by CD11b
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strategies to delay the process of denervated muscle atrophy are limited, in part because the microenvironmental function of the target muscle is not well understood. Immune microenvironment remodelling is one of the main changes of skeletal muscle environment after denervation. Our previous work found that denervated atrophic muscles recruit a large number of neutrophils and macrophages, and neutrophils can delay muscle atrophy, but the specific mechanism is still unclear. In this study, the expression of S100a8/S100a9 was significantly up-regulated in the transcriptional group of early denervated skeletal muscle. Immunofluorescence, flow sorting and quantitative PCR analysis showed that S100A8/S100A9 mainly came from neutrophils. Further knockout of S100a9 has the same effect as blocking neutrophils to aggravate muscle atrophy. Through MerTK blockers, it is clear that MerTK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.